한글목차

수년 동안 PTPN2는 "치료할 수 없는" 표적으로 분류되어 왔으며, PTPN2 억제제는 현재 면역 치료의 유력한 후보로 떠오르고 있습니다. 많은 기업들이 이러한 저분자 화합물 개발에 적극적으로 참여하고 있으며, 이 분야는 더 이상 '만약'이 아닌 '얼마나 빨리' 의미 있는 임상 검증에 도달할 수 있느냐에 달려 있습니다.

면역관문억제제 시장 규모는 현재 484억 2,000만 달러, 2023년에는 1,542억 5,000만 달러, 2030년에는 1,542억 5,000만 달러에 달할 것으로 예상되며, 암 발병률 증가, 헬스케어 지출 증가, 체크포인트 억제제의 용도 확대로 CAGR 17.9%로 성장할 것으로 예상됩니다.

체크포인트 억제제(PD-1, PD-L1, CTLA-4)는 암 치료에 혁명을 가져왔지만, 업계는 이제 모든 종양이 반응하지 않는다는 새로운 현실에 직면하고 있습니다. PTPN2 억제제는 세포 표면의 수용체를 차단하는 대신 세포 내에서 작용하여 T세포의 활성화를 촉진합니다. 이러한 세포 내 면역 조절은 표준 면역요법에 실패한 환자에게 새로운 반응을 가져올 수 있습니다.

ABBV-CLS-484(AbbVie/Calico)는 진행성 고형암에 대한 임상시험 중. AbbVie와 Calico Life Sciences는 암을 포함한 노화 및 노화 관련 질환에 초점을 맞추고 10억 달러의 추가 투자로 제휴를 확대했습니다. 베링거인겔하임은 네리오 테라퓨틱스(Nerio Therapeutics)를 13억 달러에 인수하여 PTPN1과 PTPN2를 두 배로 늘렸다.

Eilean Therapeutics는 Ness Therapeutics를 인수하여 안전성 프로파일을 개선한 동급 최고의 PTPN2 억제제 개발을 목표로 하고 있습니다. Eilean Therapeutics는 Expert Systems와의 제휴를 확대하여 AI를 활용한 신약개발을 통합함으로써 PTPN2 억제제 개발을 가속화하고 있습니다.

세계의 PTPN2 억제제 시장에 대해 조사 분석했으며, 시장 현황과 함께 인수합병, 라이선싱 및 제휴 계약, 경쟁 상황, 시장 기회 등의 정보를 전해드립니다.

목차

제1장 보고서 개요

제2장 개요

• PTPN2 억제제 소개와 역할
• PTPN2 억제제에 관한 잠재적 우려
• PTPN2 억제제 : 종양학의 매우 유망한 표적
• PTPN2 억제제 임상 응용

제3장 PTPN2 억제제 파이프라인 분석

• 개요
• 적응증/상별 자산
• 개발 단계별 파이프라인 제품
• PTPN2 억제제 경쟁 구도
• 기업별 및 상별 파이프라인 제품
• PTPN2 억제제 임상 및 규제 타임라인

제4장 PTPN2 억제제 인수, 라이선싱 및 제휴 계약

• PTPN2 억제제 인수, 라이선싱 및 거래 가치
• PTPN2 억제제 인수, 라이선싱(거래 유형별, 상별 총액)
• 개발중인 유망한 기술

제5장 PTPN2 억제제 파이프라인 상황

• 프로파일 개요
• 후기 단계 자산 비교 개요
• PTPN2 억제제 파이프라인 약제 프로파일
  • ABBV CLS 579(AbbVie/Calico Life Sciences)
  • ABBV CLS 484(AbbVie/Calico Life Sciences)
  • AB-1015(Arsenal bio)
  • HDM 2010(Hangzhou Zhongmei Huadong Pharmaceutical)
  • PTPN2 억제제(Eilean Therapeutics)
  • PTPN1/N2 억제제(Boehringer Ingelheim)
  • 기타

제6장 PTPN2 억제제의 향후 전망

제7장 SWOT 분석

제8장 부록

영문목차

For years, PTPN2 has been labeled as an "undruggable" target-a challenge too complex, a surface too shallow. But the industry has learned that what was undruggable yesterday becomes tomorrow's breakthrough, and PTPN2 inhibitors are now emerging as a serious contender in immunotherapy. With many companies actively developing these small molecules, the field is no longer about "if" but "how fast" these assets can reach meaningful clinical validation.

The immune checkpoint inhibitors market is currently valued at $48.42 billion in 2023, projected to reach $154.25 billion by 2030, growing at a CAGR of 17.9% due to the rising cancer prevalence, increased healthcare expenditure, and expanding applications of checkpoint inhibitors.

The Science: What Makes PTPN2 Different?

Checkpoint inhibitors (PD-1, PD-L1, CTLA-4) revolutionized cancer care, but the industry is now facing a new reality-not all tumors respond. PTPN2 inhibitors offer an alternative, working inside the cell to enhance T-cell activation instead of blocking receptors on the surface. This intracellular immune modulation could unlock new responses in patients who fail standard immunotherapies.

The Market: A Race for Clinical Validation

Despite their potential, PTPN2 inhibitors are still in early-stage development-but the right players are making big bets:

• ABBV-CLS-484 (AbbVie/Calico) is in trials for advanced solid tumors. AbbVie and Calico Life Sciences extended their partnership with an additional $1 billion investment, focusing on aging and age-related diseases, including oncology.
• Boehringer Ingelheim made a $1.3 billion move by acquiring Nerio Therapeutics, doubling down on PTPN1 and PTPN2.
• Eilean Therapeutics acquired Ness Therapeutics, aiming to develop best-in-class PTPN2 inhibitors with improved safety profiles. Eilean Therapeutics expanded its collaboration with Expert Systems, integrating AI-driven drug discovery to accelerate PTPN2 inhibitor development

Challenges & Development Hurdles

Despite promising therapeutic potential, PTPN2 inhibitors face key development challenges:

• Unfavorable pharmacokinetics, due to the highly cationic active site and shallow protein surface.
• Clinical uncertainties, with many candidates in early-stage trials requiring further validation.
• Need for combination therapies, often tested alongside anti-PD-1 therapies to enhance efficacy.

Market & Pipeline Insights: 2025 Report Highlights

The PTPN2 Inhibitor - Pipeline Analytics 2025 Report by Mellalta Meets provides an in-depth analysis of the market opportunity and competitive landscape across multiple indications, including oncology, cardiovascular, and cognitive disorders.

Key coverage areas include:

• Competitive Analysis - Breakdown of Companies and Products (Discovery to phase III)
• Pipeline Drug Profiles - Stages of development, intervention types, clinical trials
• Clinical Developments - Trials by region, efficacy outcomes, safety considerations
• Business & Investment Trends - Licensing agreements, funding, and collaborations
• Strategic Opportunities - Market drivers, challenges, and future outlook
• Recent and upcoming events

Table of Content

1. REPORT OVERVIEW

2. OVERVIEW

• 2.1. Introduction and Role of PTPN2 inhibitors
• 2.2. Potential Concern with PTPN2 inhibitors
• 2.3. PTPN2 inhibitors: A Highly-Potential Target in Oncology
• 2.4. Clinical Applications of PTPN2 inhibitors

3. PTPN2 INHIBITOR PIPELINE ANALYSIS

• 3.1. Overview
• 3.2. Assets by Indication/Phase
• 3.3. Pipeline Products by Stage of Development
• 3.4. PTPN2 inhibitor Competitive Landscape
• 3.5. Pipeline Products by Company and Phases
• 3.6. PTPN2 inhibitor Clinical & Regulatory Timelines

4. PTPN2 INHIBITOR ACQUISITIONS, LICENSING AND COLLABORATION DEALS

• 4.1. PTPN2 inhibitor Acquisitions, Licensing and Deal values
• 4.2. PTPN2 inhibitor Acquisitions, Licensing by Transaction type and total amount size by Phases
• 4.3. Promising Technologies Under development

5. PTPN2 inhibitor PIPELINE LANDSCAPE

• 5.1. Profile at Glance
• 5.2. Late-Stage Assets Comparisons At-a-glance
• 5.3. PTPN2 inhibitor Pipeline Drug Profiles
  • 5.3.1. ABBV CLS 579 (AbbVie/Calico Life Sciences)
    • 5.3.1.1. Product Profile & Description
    • 5.3.1.2. Collaborations
    • 5.3.1.3. Other Developments
    • 5.3.1.4. Clinical Trials
  • 5.3.2. ABBV CLS 484 (AbbVie/Calico Life Sciences)
    • 5.3.2.1. Product Profile & Description
    • 5.3.2.2. Collaborations
    • 5.3.2.3. Other Developments
    • 5.3.2.4. Clinical Trials
  • 5.3.3. AB-1015 (Arsenal bio)
    • 5.3.3.1. Product Profile & Description
    • 5.3.3.2. Collaborations
    • 5.3.3.3. Other Developments
    • 5.3.3.4. Clinical Trials
  • 5.3.4. HDM 2010 (Hangzhou Zhongmei Huadong Pharmaceutical)
    • 5.3.4.1. Product Profile & Description
    • 5.3.4.2. Collaborations
    • 5.3.4.3. Other Developments
  • 5.3.5. PTPN2 inhibitors (Eilean Therapeutics)
    • 5.3.5.1. Product Profile & Description
    • 5.3.5.2. Collaborations
    • 5.3.5.3. Other Developments
  • 5.3.6. PTPN1/N2 inhibitors (Boehringer Ingelheim)
    • 5.3.6.1. Product Profile & Description
    • 5.3.6.2. Collaborations
    • 5.3.6.3. Other Developments
  • 5.3.7. Others...

6. PTPN2 INHIBITOR FUTURE PROSPECTS

7. SWOT ANALYSIS

8. APPENDIX